Sort by:
Results Per Page:
Potent and selective BET bromodomain inhibitor; cell permeable
(+)-JQ1 based Degrader (PROTAC®) that preferentially degrades BRD4
BET bromodomain inhibitor; also promotes differentiation of hiPSCs into megakaryocytes
ERK5/BMK1 inhibitor; also BRD4 inhibitor
Negative Control for MZ 1 (Cat. No. 6154)
(+)-JQ1 based Degrader (PROTAC®) targeting BET bromodomains, active in vivo
Potent and selective (+)-JQ1 based Degrader (PROTAC®) targeting BET bromodomains, active in vivo
BET bromodomain inhibitor
Broad spectrum bromodomain inhibitor
BET bromodomain inhibitor; arrests cell cycle at G1 phase
BET bromodomain inhibitor; orally bioavailable
(+)-JQ1 based PROTAC® with selectivity for BRD4
Potent and high affinity BET bromodomain inhibitor; anti-inflammatory; orally bioavailable.
Potent BET bromodomain PROTAC®; also degrades BRD-tagged chimeric antigen receptors (CAR) in T cells
Photoswitchable BET bromodomain Degrader (PHOTAC)
Potent and selective pan-BD2 inhibitor; orally bioavailable
Potent and selective SMARCA2/4 and PB1(bromo 5)-selective SWI/SNF bromodomain inhibitor
Functionalized BET bromodomain ligand; precursor for Tag Degraders
JQ1-maleimide functionalized probe; induces proteasomal degradation of BRD4
Fluorescent BET bromodomain probe; suitable for use in TR-FRET
